One estimate put worldwide number of people suffering from diabetes to approximately 347 million, 90% of patients having Type II diabetes. Another study states that in 2010 diabetes mellitus affected nearly 285 million peoples and expected to affect 438 millions by 2030.
Gestational Diabetes is insulin-resistance in pregnant women during the period of pregnancy. It can cause various fatal compilations and is an under-diagnosed condition worldwide. It is a version of type II diabetes and usually corrects itself post-pregnancy. However women who have had gestational diabetes, have a 20-50% likelihood of developing chronic type II diabetes within 15 years of the gestational diabetes pregnancy.
According to the International Diabetes Federation, the global incidence of diabetes among adults aged 20-79 years old was 6.6% in 2010, and will increase to 7.8% by 2030. About 220 million people worldwide have diabetes and this figure will reach 336 million by 2030. market opportunities are greatest in emerging countries, as 80% of all new cases of diabetes are expected to be reported by 2025.
Also, the incidence of childhood onset type 1 diabetes in the under 15 age group is increasing in many countries in the world. Annually, about 76,000 children aged below 15 years old develop type 1 diabetes worldwide. This large and growing number of insulin-dependent diabetes patients – especially in the US, Western Europe and Japan – has resulted in an increasing demand for insulin
Diabetes Related Markets
The global diabetes therapeutics devices and drugs market is expected to reach USD 72.4 billion by 2018, growing at a CAGR of 10.4% from 2011 to 2018, whereas the global diagnosis and monitoring devices market is expected to reach USD 26.0 billion by 2018, growing at CAGR of 7.8% for the same period. The glucose meter market is forecasted to grow annually at a rate of 10.8% for the next several years and will reach more than 19.6 billion dollars in 2015. The global insulin market was worth $12,46.3 millions in 2011 and is expected to reach $32,346.7 millions in 2018 growing at a compound annual growth rate of 12% from 2011 to 2018. In the global market, China is expecting to increase its share in the global insulin market to 10.2% by 2018. The China insulin market is projected to grow very fast. It was estimated at $723.8 millions in 2011 and is projected to reach $3,299.1 millions by the year 2018. The global insulin delivery devices market is expected to grow at a compound annual growth rate (CAGR) of 6.8% between 2009 and 2016, reaching $10.8 billion in 2016.
Non Invasive Glucometer
All present glucometers are invasive. Problem: phobia, children. Two type in development:
Non-expensive, will require personally adapted (adjusted) device
Medium priced device which will not require to be personally adapted.
There were many attempts to build non invasive glucometer. Only one device was allowed by FDA ever but it was quickly withdrawn from the market due to patient’s complications The market for non invasive glucometers important not only for diabetic patients but for several other groups which may have the risk of developing diabetes:
elderly, overweighed etc.
pregnant women to monitor levels of glucose in the blood due to the gestation diabetes.
Babes - the measurement of the level of glucose in the blood of infants (babies) is the ONLY way to determine the level of infants satiability (how full the baby is after breast feeding)
The Company is developing non-invasive glucometer based on the mix of technologies (IR technology, IR spectrometer and Raman spectrometer).
Solution for Diabetes Mellitus
The company approach is very close to the concept of artificial pancreas based on implanting bioengineered tissues which would secrete the amount of insulin and other glucagons needed in response to sensed glucose. Bioengineered tissues will be encapsulated in the nanotubes. Such nanotubes are engineered in such a way that it shall be possible to avoided proliferating immune response but to allow the diffusion of nutrients and secreted hormones. It will prevent a foreign body response resulting in a fibrotic reaction. It is important to point that this approach permits to achieve insulin independence without immunosuppressant drugs.
Early Detection of Cancer (stage I and II)
The member of our scientific panel Dr. Kapelushnik was able to prove existence of special markers in the blood for several types of cancer. The study was validated for the several types of cancer. The company has preliminary design of medical devices for the non-invasive checking of such markers and for the mass screening of population. The finding of Dr. Kapelushnik will be validated for other types of cancer and additional studies will be required, the field is very promising It is impossible to estimate the market because there is nothing similar on the market. However, the global cancer therapies market is expected to the reach $162.5 billion by 2015. the Company believes that the sizable part of the market could be taken by this technology
Detection of Early Signs of Pulmonary Edema (IR Technologies)
Direct measurement of liquid in the parenchyma & air space of the lung, especially in the alveoli.
Direct detection of low oxygen saturation of the blood
Measurement of pumping function of the hard
Measurement of blood pressure in the blood vessels of the lung, especially measurement of the central venous pressure.
Detection of indication for cardiogenic pulmonary edema
Detection of indication for non-cardiogenic pulmonary edema
Solution of the Pulmonary Edema (Nanotubes technology)
Delivery of nanotubes (of various type) to the lungs and even to the alveoli and holding them there (control)
Delivery of nanotubes with the drugs in controlled way to the lungs
Delivery of nanotubes with the mix of gases to the lung in general and to alveoli in controlled way
Delivery of nanotubes with the gas generating substances to the alveoli in the case of pulmonary edema risk as well as in the case of elderly patients.
Opening of the selected nanotubes in the selected places (pin point delivery; right time, right place).
Early Detection of Brain Edema (Nanotubes technology)
Monitoring level of water, sodium and potassium inside the brain.
Tracking of the rise of the level of water and sodium in the brain
Detection of signs of changes in the morphology including:
- brain becoming soft, smooth, overfilling
the cranial vault.
- Gyro becomes flattened
- Sulci becomes narrowed
- Ventricular cavities becomes compressed
- Monitoring of intracranial pressure
Solution to the Brain Edema (Swelling of the Brain)
Delivery of nanotubes (of various type) to the:
Main arteries near main entrance to the brain and holding nanotubes there (control).
Blood vessels in the brain and holding in the area of danger (control).
Automatic release of nanotubes to the brain from the arteries
Opening nanotubes in the area of interest of the brain
Study of Intracranial Pressure:
Measurement of intracranial pressure using indicators based on nanotubes.
Measurement of intracranial pressure using instruments based on Infra Red (IR) technology
Smart Chemical Therapy
The chemotherapy market is bigger than $42 billion. The average annual cost for chemotherapy drugs per user was of $22,350 (as of 2007). The chemotherapy is used for the treatment of various types of cancer that seek to destroy cancer cells. The toxic chemicals usually have detrimental and sometimes debilitating effect on the patient, because such chemicals also attack healthy cells in the patient’s body. There are hundreds of chemicals offered on the market. The Company developed a novel & revolutionary way of delivery of such drugs directly to the tumor using nanotubes technology. The Company’s technology permits to hold nanotubes with toxic chemicals on the tumor or near the tumor. The Company’s solution will permit to release toxic drugs affecting the tumor and practically not affecting other cells. The Company will not compete with the drug companies. The drug companies will be partners of the Company. The Company may become a supplier of specially designed nanotubes to the drug companies, or the Company may become the packaging house (packing the drugs produced by the drug companies in our nanotubes) and may become distributor of the drugs which are packed into nanotubes.